Zanubrutinib shows durable efficacy in CLL/SLL with 17p deletions, according to 5-year SEQUOIA trial data.

Zanubrutinib plus venetoclax elicited durable responses in patients with treatment-naïve CLL or SLL and high-risk genetic features.

Switching patients with chronic lymphocytic leukemia (CLL) from ibrutinib to zanubrutinib has led to fewer cardiac side effects and a reduced workload for Mohit Narang, MD, managing partner at ...

A zanubrutinib, venetoclax, and obinutuzumab triplet achieved deep remissions and high undetectable measurable residual ...

Lenvatinib Plus Pembrolizumab and Chemotherapy Versus Chemotherapy in Advanced Metastatic Gastroesophageal Adenocarcinoma: The Phase III, Randomized LEAP-015 Study Authors retain all rights in any ...

BeiGene , Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that will change its name to BeOne Medicines Lt ...

The latest news from ASCO 2025 focusing on CLL including abstracts, features, and helpful conference information.

“We adjusted for multiple clinical factors ... with newer BTK inhibitors such as acalabrutinib and zanubrutinib (Brukinsa, BeiGene). Research has already begun into the potential role of ...

Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive final results from the overall survival (OS) analysis of the Phase III INAVO120 study. These data showed ...

XTI Aerospace, Inc. ("XTI"), a pioneer in xVTOL and powered-lift aircraft solutions, today announced the Federal Aviation Administration ("FAA") has selected the Ft. Worth, Texas Certification Branch ...

1State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology and Blood Diseases Hospital, Chinese ...